- Lobbying
- Lobbying by Nektar Therapeutics
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Remy Brim | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing |
Brent Del Monte | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee See prior filing |
John Stone | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Ctme Health Subcommittee Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Ctme Health Subcommittee See prior filing |
Robb Walton | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi See prior filing |
Matthew Hoffmann | St. Asst. Rep. Vitter; LC Rep. Vitter; Sen. LC .Rep. Vitter; LA Rep. Paul Ryan; Sen. LA Rep. Paul Ryan; LD Rep. Paul Ryan; Budget Analyst Rep. Paul Ryan; St. Dir. Health Subcmte House W&M Cmte; Policy Analyst Off. Speaker; Policy Dir. Sen. Fin Cmte. See prior filing |
Daniel Farmer | St. Asst Rep. Debbie Wasserman Schultz; Leg. Corr. Rep. Debbie Wasserman Schultz; Leg. Corr./Leg. Asst. Rep. Debbie Wasserman Schultz; Leg. Asst. Rep. Zack Space; Sr. Leg. Asst. Rep. Zack Space; Leg. Dir. Zack Space See prior filing |
Joel Bailey | COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Matsui; LA / Sr. LA Rep. Baron Hill See prior filing |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Drug development, review and coverage related issues..
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Drug development, review and coverage related issues..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate